Merz concludes enrolment in Phase III Xeomin trials for migraine

Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin for adult migraine prevention. The studies enrolled around 1800 participants to test the drug's safety and efficacy in preventing both chronic and episodic migraine. Migraine involves recurrent attacks of moderate to severe head pain, frequently accompanied by sensitivity to light and sound. Credit: Tunatura/Shutterstock.com. Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin (incobotulinumtoxinA) for adult migraine prevention. The studies enrolled around 1800 participants to test the therapy’s safety and efficacy in preventing…

Source: Clinical Trials Arena